Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.34 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5581743 | 0.89 | ALDH1A1 (0.40) | ALDH1A1KDRSIK2PDE4D | |
| SCHEMBL5582307 | 0.89 | PDE4B (0.41) | ALDH1A1SCN9ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5581786 | 0.89 | ALDH1A1 (0.41) | ALDH1A1LRRK2KITSCN9AKDR | |
| SCHEMBL5581811 | 0.85 | PDGFRB (0.43) | ALDH1A1LRRK2SCN9ASIK2ADORA1 | |
| SCHEMBL5581749 | 0.85 | FYN (0.43) | SCN9ASIK2CSNK2A1SCN5AADORA1 | |
| SCHEMBL5582243 | 0.83 | IDO1 (0.42) | KITADORA1 | |
| SCHEMBL5581909 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LRRK2SCN9AKDRSIK2 | |
| SCHEMBL5582341 | 0.82 | PDE4D (0.45) | ALDH1A1KITPDE4D | |
| SCHEMBL5582236 | 0.80 | LRRK2 (0.43) | ALDH1A1LRRK2SIK2CRHR1PDE4D | |
| SCHEMBL5582151 | 0.80 | KIT (0.47) | KITSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | ALDH1A1 1519/4885LRRK2 176/4885KIT 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.